logo
Prediction: 2 Stocks Will Be Worth More Than Palantir Technologies in 2026

Prediction: 2 Stocks Will Be Worth More Than Palantir Technologies in 2026

Yahoo04-05-2025
Palantir is currently worth $269 billion, but certain Wall Street analysts think Intuitive Surgical and ServiceNow can top that figure in 2026.
ServiceNow is a leader in IT service management and IT operations software, and recently released AI products are driving revenue growth.
Intuitive Surgical is a technology leader in robotics-assisted surgical systems, and it recently won new approvals from the FDA.
Palantir Technologies is currently worth $269 billion. But these Wall Street analysts think Intuitive Surgical (NASDAQ: ISRG) and ServiceNow (NYSE: NOW) can top that figure in 2026:
Patrick Wood at Morgan Stanley has set Intuitive Surgical with a bull-case target price of $850 per share. That implies 64% upside from its current share price of $517. It also implies a market value of $304 billion.
Patrick Walravens at JMP Securities has set ServiceNow at a target price of $1,300 per share. That implies 36% upside from its current share price of $955. It also implies a market value of $270 billion.
Here's what investors should know about these stocks.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Intuitive Surgical is the leader in robotics-assisted surgery. It is best known for its da Vinci systems, which let surgeons perform minimally invasive procedures with greater precision in five areas:
General surgery
Urologic surgery
Gynecologic surgery
Cardiothoracic surgery
Head and neck surgery
The company also provides Ion systems for minimally invasive lung biopsies.
Importantly, Intuitive has a razor-and-blade business model. Surgical and diagnostic systems are the razors; they represent significant but infrequent expenses for healthcare facilities. And the adjacent instruments and accessories are the blades; they include consumable tools like scalpels and forceps that must be replaced with each procedure. The razor-and-blade model creates a steady revenue stream.
Intuitive Surgical reported strong first-quarter financial results that beat estimates on the top and bottom lines. Revenue rose 19% to $2.2 billion on strong growth in da Vinci procedures and system placements. Meanwhile, non-GAAP (generally accepted accounting principles) earnings rose 21% to $1.50 per diluted share.
Intuitive is well positioned to keep its momentum. Recently, the company won approvals from the Food and Drug Administration that let da Vinci systems perform more colorectal surgical procedures. In a note to clients, Morgan Stanley analyst Patrick Wood said the total addressable market is "larger than investors might appreciate." So, the new approval could lead to faster-than-expected growth in the coming quarters.
Wall Street says adjusted earnings will increase 10% annually through 2026, but analysts have often missed the mark. Intuitive Surgical beat the consensus estimate by an average of 14% in the last four quarters. If earnings grow at 28% annually -- equal to growth in 2024 -- through the third quarter of 2026, its market value could reach $270 billion without any change in the price-to-earnings (P/E) ratio.
However, Intuitive shares currently trade at 68 times earnings, an expensive valuation for a company forecast to grow earnings at 10% annually. So, my prediction is admittedly a long shot. The company would need a series of very strong financial results to top Palantir's current market value in 2026, and the bull-case target set by Morgan Stanley seems unlikely. Regardless, patient investors should consider buying a small position in this robotics stock today.
ServiceNow provides workflow management software that helps businesses organize and digitize processes across departments. Its core competency is IT software. It is the market leader in IT service management and artificial intelligence (AI) for IT operations software. Importantly, the company added generative AI features called Now Assist in 2023, and agentic AI capabilities in 2025.
ServiceNow reported solid financial results in the first quarter, beating estimates on the top and bottom lines. Revenue increased 18% to $3 billion, and non-GAAP net income increased 18% to $4.04 per diluted share. "ServiceNow's position as the platinum standard for enterprise-grade AI drove these outstanding first-quarter results," CEO Bill McDermott told analysts. "The software industrial complex is converging on ServiceNow as the AI operating system for the enterprise."
Wall Street expects ServiceNow's adjusted earnings to grow at 19% annually through 2026, but the company beat the consensus estimate by an average of 7% over the last six quarters. If that trend persists through the third quarter of 2026, trailing-12-month earnings would hit $20.10 per share. If ServiceNow keeps its current valuation of 66 times earnings, its share price would hit $1,325, implying 39% upside from the current price.
In that scenario, ServiceNow would hit a market value of $275 billion after reporting third-quarter financial results in 2026, more than Palantir is worth today. However, the current valuation is expensive for a company forecast to grow earnings at 19% annually, which means ServiceNow needs flawless execution to hit that mark.
Before you buy stock in Intuitive Surgical, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Intuitive Surgical wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $611,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $684,068!*
Now, it's worth noting Stock Advisor's total average return is 889% — a market-crushing outperformance compared to 162% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of April 28, 2025
Trevor Jennewine has positions in Palantir Technologies. The Motley Fool has positions in and recommends Intuitive Surgical, Palantir Technologies, and ServiceNow. The Motley Fool has a disclosure policy.
Prediction: 2 Stocks Will Be Worth More Than Palantir Technologies in 2026 was originally published by The Motley Fool
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SM Energy (SM) Gets a Hold from Wells Fargo
SM Energy (SM) Gets a Hold from Wells Fargo

Business Insider

time32 minutes ago

  • Business Insider

SM Energy (SM) Gets a Hold from Wells Fargo

Wells Fargo analyst Hanwen Chang maintained a Hold rating on SM Energy on July 18 and set a price target of $30.00. The company's shares closed last Friday at $25.89. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Chang covers the Energy sector, focusing on stocks such as Vital Energy, Matador Resources, and SM Energy. According to TipRanks, Chang has an average return of -2.8% and a 38.24% success rate on recommended stocks. In addition to Wells Fargo, SM Energy also received a Hold from J.P. Morgan's Zach Parham in a report issued on July 10. However, on July 16, Siebert Williams Shank & Co maintained a Buy rating on SM Energy (NYSE: SM). Based on SM Energy's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $844.54 million and a net profit of $182.27 million. In comparison, last year the company earned a revenue of $559.87 million and had a net profit of $131.2 million Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is neutral on the stock. Last month, Richard A. Jenkins, the SVP – Utah of SM sold 7,726.00 shares for a total of $220,113.74.

Morgan Stanley Lifts PT on T-Mobile US (TMUS) to $280 from $265, Keeps Overweight Rating
Morgan Stanley Lifts PT on T-Mobile US (TMUS) to $280 from $265, Keeps Overweight Rating

Yahoo

time32 minutes ago

  • Yahoo

Morgan Stanley Lifts PT on T-Mobile US (TMUS) to $280 from $265, Keeps Overweight Rating

T-Mobile US, Inc. (NASDAQ:TMUS) is one of the best long term low volatility stocks to buy now. On July 16, Morgan Stanley raised the firm's price target on T-Mobile US, Inc. (NASDAQ:TMUS) to $280 from $265, keeping an Overweight rating on the shares. A customer checking out their new device at a T-Mobile store, illustrating the convenience and accessibility of retail stores. The firm told investors in a research note that it raised the estimates for free cash flow for US operators after the newly signed tax law. It further stated that capacity is likely to be allocated to a mix of fiber builds, buybacks, and/or other M&A. Morgan Stanley also added that while competition is intense, it is not clear whether it is intensifying. T-Mobile US, Inc. (NASDAQ:TMUS) provides wireless communications services under the T-Mobile and MetroPCS brands. The company offers prepaid and postpaid wireless messaging, voice, and data services, along with wholesale wireless services. While we acknowledge the potential of TMUS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT
Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT

Yahoo

time32 minutes ago

  • Yahoo

Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT

AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to buy now. On July 10, Morgan Stanley analyst Terrence Flynn reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) and set a price target of $250.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported positive fiscal Q1 2025 results that support the optimistic outlook, with adjusted diluted EPS reaching $2.46, experiencing a 6.5% growth. The company also reported $13.343 billion in net revenue for the first quarter of 2025, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store